stockportfolio.pro
Sarepta Therapeutics, Inc. (SRPT)
Healthcare · Biotechnology · NasdaqGS
Sarepta Therapeutics, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.42M | $154.58M | $301.03M | $380.83M | $540.10M | $701.89M | $933.01M | $1.24B | $1.90B | $2.20B |
| Gross profit | $5.29M | — | — | — | — | — | — | — | — | $2.17B |
| Net income | $-267.26M | $-50.69M | $-361.92M | $-715.08M | $-554.13M | $-418.78M | $-703.49M | $-535.98M | $235.24M | $-713.41M |
| Net margin | -4930.2% | -32.8% | -120.2% | -187.8% | -102.6% | -59.7% | -75.4% | -43.1% | 12.4% | -32.5% |
Source: Sarepta Therapeutics, Inc. SEC filings (10-K). 17 years of history available in the interactive view.
Explore 17 years of Sarepta Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track SRPT in your portfolio →
About Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Sarepta Therapeutics, Inc. — frequently asked questions
What is Sarepta Therapeutics, Inc.'s revenue?
Sarepta Therapeutics, Inc. (SRPT) reported revenue of $2.20B for fiscal year 2025, up 15.6% from the prior year, according to its SEC filings.
Is Sarepta Therapeutics, Inc. profitable?
No — SRPT reported a net loss of $-713.41M in fiscal 2025.
What is SRPT's P/E ratio?
Sarepta Therapeutics, Inc. trades at a price-to-earnings ratio of about 43.0 based on the latest data in our nightly-refreshed cache.
How fast is Sarepta Therapeutics, Inc. growing?
SRPT's revenue grew at roughly 32.4% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from Sarepta Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 17 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.